Press Releases

Sep 04, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 28, 2020 Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020
Aug 27, 2020 Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
Aug 07, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 05, 2020 Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
Jul 20, 2020 Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
Jul 09, 2020 Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
Jul 02, 2020 Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 25, 2020 Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
Jun 22, 2020 Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II